Tuesday, November 13, 2012 9:15:29 AM
7:23 AM 11/12/2012 - StreetInsider
Leerink Swann reiterated their Outperform rating on Medivation (NASDAQ: MDVN), saying Xtandi appears to be off to a fast start.
The firm comments, "As previously reported by Astellas and in an 8-K by MDVN, US Xtandi sales were $14.1M for the 12 shipping days in the 3Q12. We believe this represents a good start of the commercial launch, though a substantial portion was likely related to stocking and patients rolling over from the EAP. MDVN announced that Phase III clinical trials for Xtandi are being planned, although the indications are in discussion with partner Astellas and will be publicly announced at a later date."
Shares of Medivation closed at $45.70 yesterday, with a 52 week range of $38.82-$113.00. (NOTE- high was from pre-split)
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM